Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:APGENASDAQ:INDVNASDAQ:IRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.62+2.9%$5.10$3.55▼$11.16$455.82M1.132.84 million shs3.86 million shsAPGEApogee Therapeutics$40.98+8.8%$36.39$26.20▼$63.50$1.89B1.7539,830 shs1.11 million shsINDVIndivior$14.07+3.5%$10.77$7.33▼$17.09$1.94B0.661.08 million shs1.87 million shsIRONDisc Medicine$50.02+4.2%$44.80$30.82▼$68.73$1.73B0.73347,320 shs223,217 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-0.55%-2.67%+8.55%-1.97%-25.21%APGEApogee Therapeutics+3.15%-0.11%+5.85%+4.18%-14.14%INDVIndivior-0.59%+9.51%+16.15%+40.10%-23.69%IRONDisc Medicine+1.46%+2.43%+12.40%-13.76%+26.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.8238 of 5 stars3.51.00.00.03.73.30.6APGEApogee Therapeutics2.3328 of 5 stars3.51.00.00.02.44.20.0INDVIndivior1.7264 of 5 stars1.63.00.00.02.61.71.9IRONDisc Medicine1.9534 of 5 stars3.51.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20259.43% UpsideAPGEApogee Therapeutics 3.00Buy$94.60130.84% UpsideINDVIndivior 3.25Buy$15.006.61% UpsideIRONDisc Medicine 3.09Buy$98.8097.52% UpsideCurrent Analyst Ratings BreakdownLatest ALT, INDV, APGE, and IRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.003/11/2025APGEApogee TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$90.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K22,791.07N/AN/A$2.75 per share2.04APGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/AINDVIndivior$1.17B1.66$2.85 per share4.94N/A∞IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)APGEApogee Therapeutics-$83.99M-$3.60N/AN/AN/AN/A-21.81%-20.94%8/11/2025 (Estimated)INDVIndivior$2M-$0.31N/A8.23N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%8/6/2025 (Estimated)Latest ALT, INDV, APGE, and IRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87APGEApogee TherapeuticsN/A16.3916.39INDVIndiviorN/A0.830.65IRONDisc MedicineN/A19.3619.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%APGEApogee Therapeutics79.04%INDVIndivior60.33%IRONDisc Medicine83.70%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%APGEApogee Therapeutics42.77%INDVIndiviorN/AIRONDisc Medicine4.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million68.21 millionOptionableAPGEApogee Therapeutics9146.05 million28.77 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableIRONDisc Medicine3034.63 million28.50 millionNot OptionableALT, INDV, APGE, and IRON HeadlinesRecent News About These CompaniesAmeriprise Financial Inc. Invests $335,000 in Disc Medicine, Inc. (NASDAQ:IRON)June 6 at 3:19 AM | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Receives $98.80 Average Price Target from BrokeragesJune 6 at 1:29 AM | americanbankingnews.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 74,454 Shares of Disc Medicine, Inc. (NASDAQ:IRON)June 3 at 3:57 AM | marketbeat.comBank of America Corp DE Reduces Position in Disc Medicine, Inc. (NASDAQ:IRON)June 3 at 3:18 AM | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Buy" from AnalystsJune 3 at 1:33 AM | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Nuveen Asset Management LLCJune 2, 2025 | marketbeat.comWellington Management Group LLP Sells 444,821 Shares of Disc Medicine, Inc. (NASDAQ:IRON)May 30, 2025 | marketbeat.comDisc Medicine to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comDisc Medicine, Inc. (NASDAQ:IRON) Stock Position Raised by Deutsche Bank AGMay 28, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 742,423 Shares of Disc Medicine, Inc. (NASDAQ:IRON)May 25, 2025 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 6,677 Shares of StockMay 23, 2025 | insidertrades.comWoodline Partners LP Boosts Stake in Disc Medicine, Inc. (NASDAQ:IRON)May 23, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Rafferty Asset Management LLCMay 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Acquires Shares of 81,190 Disc Medicine, Inc. (NASDAQ:IRON)May 19, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Northern Trust CorpMay 19, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) is MPM Bioimpact LLC's 7th Largest PositionMay 16, 2025 | marketbeat.com56,400 Shares in Disc Medicine, Inc. (NASDAQ:IRON) Bought by Patient Square Capital LPMay 16, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Disc Medicine, Inc. (NASDAQ:IRON)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Grows Stock Position in Disc Medicine, Inc. (NASDAQ:IRON)May 15, 2025 | marketbeat.comDisc Medicine (NASDAQ:IRON) Price Target Raised to $120.00May 14, 2025 | marketbeat.comDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 CongressMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe Payouts3 Trades Members of Congress Are Making Right NowBy Chris Markoch | May 23, 2025View 3 Trades Members of Congress Are Making Right NowWill Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?By Gabriel Osorio-Mazilli | May 22, 2025View Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?ALT, INDV, APGE, and IRON Company DescriptionsAltimmune NASDAQ:ALT$5.62 +0.16 (+2.93%) Closing price 04:00 PM EasternExtended Trading$5.63 +0.01 (+0.25%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Apogee Therapeutics NASDAQ:APGE$40.98 +3.33 (+8.84%) Closing price 04:00 PM EasternExtended Trading$40.93 -0.05 (-0.12%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Indivior NASDAQ:INDV$14.07 +0.48 (+3.53%) Closing price 04:00 PM EasternExtended Trading$14.06 -0.01 (-0.07%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Disc Medicine NASDAQ:IRON$50.02 +2.01 (+4.19%) Closing price 04:00 PM EasternExtended Trading$50.00 -0.02 (-0.04%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
